Clinical TrialMay 18, 2026, 05:02 PM
Cullinan Therapeutics to Present Positive CLN-978 Phase 1 Data at EULAR
AI Summary
Cullinan Therapeutics announced that initial clinical data from two ongoing Phase 1 studies (OUTRACE RA and OUTRACE SLE) evaluating CLN-978 will be presented at the European Alliance of Associations for Rheumatology (EULAR) European Congress of Rheumatology from June 3-6, 2026. The abstract reports a favorable safety profile at initial dose levels, robust B cell depletion, and early signals of promising clinical activity in patients with active, treatment-refractory rheumatoid arthritis and moderate to severe systemic lupus erythematosus. Updated data, including additional patients, will be presented at the congress.
Key Highlights
- CLN-978 Phase 1 data for RA/SLE to be presented at EULAR Congress (June 3-6, 2026).
- Initial doses of CLN-978 showed a favorable safety profile.
- Robust B cell depletion observed in both peripheral blood and tissue.
- Early promising clinical activity seen in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE).
- CLN-978 is a wholly owned asset, a 65 kDa CD19xCD3 bispecific T cell engager.
- Poster presentation scheduled for June 6, 2026, 10:15 a.m. - 11:15 a.m. BST.
Price Impact
More from CGEM